Trial Profile

A phase III trial of sparsentan for Alport Syndrome

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 04 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sparsentan (Primary)
Indications Hereditary nephritis
Focus Therapeutic Use

Most Recent Events

30 Dec 2025 According to a Chugai Pharmaceutical media release, the Renalys Pharma has been acquired and merged into Chugai Pharmaceutical.
27 Nov 2025 New trial record
24 Oct 2025 According to Renalys Pharma media release, Chugai will acquire Renalys and will align development with PMDA expectations, also gaining exclusive rights to develop and commercialize sparsentan in Japan, South Korea, and Taiwan.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com